Compare H2O America (HTO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Summit Therapeutics Inc — how do they compare? H2O America trades at $58.48 (market cap $2.43B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 5.6× H2O America's market cap, and H2O America pays a 3.03% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and Summit Therapeutics Inc for 16 Days on average.
| HTO | SMMT | |
|---|---|---|
Market Cap | $2.43B | $13.71B |
Volume | 593,883 | 6,173,057 |
Sector | Utilities | Health |
52-Week High | $65.43 | $26.38 |
52-Week Low | $44.44 | $12.43 |
Typical Hold Time | 40 Days | 16 Days |
Enterprise Value | $4.22B | $13.04B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.48, up 0.86% with a bearish technical signal despite bullish oscillators. The company shows stable fundamentals with 12.91% net margin and consistent earnings beats in recent quarters. Recent Texas acquisitions signal growth strategy, though cash flow trends show heavy investment activity. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target.
HTO presents a compelling value opportunity with strong analyst support and strategic expansion, though execution risks from recent acquisitions and bearish technical indicators warrant caution. The stock's current discount to consensus target offers potential upside for patient investors willing to navigate near-term volatility.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
